117 related articles for article (PubMed ID: 16154102)
1. Prostacyclin protects against elevated blood pressure and cardiac fibrosis.
Francois H; Athirakul K; Howell D; Dash R; Mao L; Kim HS; Rockman HA; Fitzgerald GA; Koller BH; Coffman TM
Cell Metab; 2005 Sep; 2(3):201-7. PubMed ID: 16154102
[TBL] [Abstract][Full Text] [Related]
2. Getting to the heart of COX-2 inhibition.
Breyer MD
Cell Metab; 2005 Sep; 2(3):149-50. PubMed ID: 16154096
[TBL] [Abstract][Full Text] [Related]
3. Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A
D'Agostino I; Tacconelli S; Bruno A; Contursi A; Mucci L; Hu X; Xie Y; Chakraborty R; Jain K; Sacco A; Zucchelli M; Landolfi R; Dovizio M; Falcone L; Ballerini P; Hwa J; Patrignani P
Pharmacol Res; 2021 Aug; 170():105744. PubMed ID: 34182131
[TBL] [Abstract][Full Text] [Related]
4. COX-2-dependent cardiac failure in Gh/tTG transgenic mice.
Zhang Z; Vezza R; Plappert T; McNamara P; Lawson JA; Austin S; Praticò D; Sutton MS; FitzGerald GA
Circ Res; 2003 May; 92(10):1153-61. PubMed ID: 12702643
[TBL] [Abstract][Full Text] [Related]
5. COX-2-derived prostacyclin modulates vascular remodeling.
Rudic RD; Brinster D; Cheng Y; Fries S; Song WL; Austin S; Coffman TM; FitzGerald GA
Circ Res; 2005 Jun; 96(12):1240-7. PubMed ID: 15905461
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.
Kagiyama S; Matsumura K; Fukuhara M; Sakagami K; Fujii K; Iida M
Hypertens Res; 2007 Oct; 30(10):979-89. PubMed ID: 18049031
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Noda A; Izawa H; Nagata K; Yokota M
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1164-71. PubMed ID: 17184496
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling.
Jia N; Dong P; Huang Q; Jin W; Zhang J; Dai Q; Liu S
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):262-6. PubMed ID: 18785976
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective prostacyclin signaling in vascular smooth muscle.
Fetalvero KM; Martin KA; Hwa J
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):109-18. PubMed ID: 17164138
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
Loch D; Levick S; Hoey A; Brown L
J Cardiovasc Pharmacol; 2006 Mar; 47(3):396-404. PubMed ID: 16633082
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E
Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
[TBL] [Abstract][Full Text] [Related]
13. Neuronal nitric oxide synthase-deficient mice have impaired renin release but normal blood pressure.
Sällström J; Carlström M; Jensen BL; Skøtt O; Brown RD; Persson AE
Am J Hypertens; 2008 Jan; 21(1):111-6. PubMed ID: 18091753
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adeno-associated virus-mediated delivery of antisense angiotensin II receptor 1 gene attenuates hypertension development.
Li XG; Yan JT; Xu XZ; Wang JN; Cheng LM; Wang T; Zuo P; Wang DW
Acta Pharmacol Sin; 2007 Nov; 28(11):1737-45. PubMed ID: 17959024
[TBL] [Abstract][Full Text] [Related]
15. The antihypertensive effects of quercetin in a salt-sensitive model of hypertension.
Mackraj I; Govender T; Ramesar S
J Cardiovasc Pharmacol; 2008 Mar; 51(3):239-45. PubMed ID: 18356687
[TBL] [Abstract][Full Text] [Related]
16. Effects of salt loading and various therapies on cardiac hypertrophy and fibrosis in young spontaneously hypertensive rats.
Ziegelhöffer-Mihalovicova B; Arnold N; Marx G; Tannapfel A; Zimmer HG; Rassler B
Life Sci; 2006 Jul; 79(9):838-46. PubMed ID: 16624325
[TBL] [Abstract][Full Text] [Related]
17. Management of nocturnal hypertension.
Vij R; Peixoto AJ
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):607-18. PubMed ID: 19505276
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice.
Billet S; Bardin S; Verp S; Baudrie V; Michaud A; Conchon S; Muffat-Joly M; Escoubet B; Souil E; Hamard G; Bernstein KE; Gasc JM; Elghozi JL; Corvol P; Clauser E
J Clin Invest; 2007 Jul; 117(7):1914-25. PubMed ID: 17607364
[TBL] [Abstract][Full Text] [Related]
19. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
20. The effect of diet on simvastatin and losartan enhancement of endothelial function.
Bayorh MA; Layas MF; Mann G; Feuerstein GZ; Eatman D
Clin Exp Hypertens; 2007 Jul; 29(5):311-25. PubMed ID: 17653966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
